A5075657251- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Kruppel-like factors research
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Hemoglobinopathies and Related Disorders
- Chronic Myeloid Leukemia Treatments
- Blood groups and transfusion
- Blood Coagulation and Thrombosis Mechanisms
- Chronic Lymphocytic Leukemia Research
- Renal Diseases and Glomerulopathies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Lymphoma Diagnosis and Treatment
- Mesenchymal stem cell research
- Venous Thromboembolism Diagnosis and Management
- Blood properties and coagulation
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Autoimmune Bullous Skin Diseases
- Multiple Myeloma Research and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Antiplatelet Therapy and Cardiovascular Diseases
- Erythrocyte Function and Pathophysiology
Ospedale “M. Bufalini” di Cesena
2023-2024
Università Cattolica del Sacro Cuore
2016-2024
Agostino Gemelli University Polyclinic
2024
Ospedale San Bortolo
2014-2023
International Renal Research Institute of Vicenza
2013-2022
Research Institute of Economy, Trade and Industry
2014
University of Pavia
2011
University of Padua
2011
University of Florence
2011
University of Bergamo
2011
Abnormalities in the number and function of platelets may contribute to thromboembolic complications patients with essential thrombocythemia. We assessed whether maintaining platelet count below 600,000 per cubic millimeter hydroxyurea reduces incidence thrombosis thrombocythemia a high risk thrombosis.
Current treatment recommendations for patients with polycythemia vera call maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in randomized clinical trial.We randomly assigned 365 adults JAK2-positive who were being treated phlebotomy, hydroxyurea, or both to receive either more intensive (target hematocrit, <45%) (low-hematocrit group) 45 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular...
Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health Organization-defined polycythemia vera (PV). At diagnosis, median age was 61 years (51% females); thrombocytosis venous thrombosis were more frequent in women arterial abnormal karyotype men. Considering from center most mature (n=337 44% followed to death), survival (14.1 years) significantly worse than that age- sex-matched US population...
Purpose The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis (PMF). This study examined clinical relevance such a distinction. Methods Representatives seven international centers excellence for myeloproliferative neoplasms convened to create clinicopathologic database patients previously diagnosed as having ET (N = 1,104). Study eligibility included availability...
We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk thrombosis. However, relatively short follow‐up (median 27 months) did not enable evaluation developing secondary malignancies. In this study, we report long‐term outcome 114 included trial: 56 randomized to receive HU and 58 no cytoreductive therapy. Before randomization, 15 had been treated busulphan. During observation period, 29...
Summary Polycythemia vera (PV) is a chronic myeloproliferative disorder whose major morbidity and mortality are thrombohaemorragic events progression to acute leukaemia or myelofibrosis. Whether the haematocrit platelet count predict such complications remains unclear. The European Collaboration on Low‐dose Aspirin in Vera prospective study included 1638 PV patients. A total of 164 deaths (10%), 145 (8·85%) thrombosis 226 (13·8%) were encountered during 4393 person‐years follow‐up (median...
We examined the baseline features and clinical outcomes of 140 patients presenting with JAK2V617F positivity a bone marrow morphology conforming WHO criteria polycythemia vera (PV), but hemoglobin level <18.5 g/dL in males (range 16.0-18.4) <16.5 females 15.0-16.4). This cohort operationally referred to as masked PV (mPV) was compared 257 overt displayed male predominance, more frequent history arterial thrombosis thrombocytosis. Incidence similar between two groups mPV significantly higher...
Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the long-term treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It considered a first-choice agent these disorders as underlined by European Leukemia Net Consensus Conference [1], although it formally approved this indication in some countries only. The drug reportedly well tolerated large majority subjects, systemic and/or localized toxicities have been reported. criteria...
Summary Givinostat, a histone‐deacetylase inhibitor ( HDAC i), inhibits proliferation of cells bearing the JAK 2 V617F mutation and has shown significant activity with good tolerability in patients chronic myeloproliferative neoplasms MPN ). In this multicentre, open‐label, phase II study, 44 polycythaemia vera PV ), unresponsive to maximum tolerated doses MTD ) hydroxycarbamide HC were treated Givinostat (50 or 100 mg/d) combination . The European LeukaemiaNet response criteria used assess...